Angiotensin II-induced abdominal aortic aneurysm occurs independently of the 5-lipoxygenase pathway in apolipoprotein E-deficient mice

被引:27
作者
Cao, Richard Yang
Adams, Michael A.
Habenicht, Andreas J.
Funk, Colin D.
机构
[1] Queens Univ, Dept Physiol, Kingston, ON K7L 3N6, Canada
[2] Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada
[3] Queens Univ, Dept Pharmacol, Kingston, ON K7L 3N6, Canada
[4] Univ Jena, Inst Vasc Med, D-07743 Jena, Germany
关键词
aneurysm; 5-lipoxygenase; leukotriene; mouse model; inflammation;
D O I
10.1016/j.prostaglandins.2007.03.005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Genetic association studies and pathological analysis of cardiovascular disease specimens implicate a role for the 5-lipoxygenase (5-LO)/Ieukotriene (LT) pathway in human cardiovascular disease. Previously, we had detected a role for this pathway in the incidence and severity of hyperlipidemic, cholate-containing, diet-induced aortic aneurysm in mice. The goal of the present study was to assess the importance of the 5-LO/LT pathway in angiotensin II(Ang Il)-induced murine abdominal aortic aneurysm (AAA) formation. Mice with either genetic (5-LO-/-) or pharmacological (MK-0591) inhibition of the 5-LO pathway on an apolipoprotein E-deficient (apoE(-/-)) background were subjected to a normal chow diet with infusion of Ang 11 (500 ng/kg/min) for 28 days for assessment of AAA incidence and severity. Ang II-induced marked aortic wall remodeling with an incidence of 32,29 and 40% AAA formation in 5-LO-/- apoE-/-, 5-LO(+/+)apoE(-/-) and 5-LO(+/+)apoE(-/-) mice treated with FLAP inhibitor MK-0591, respectively, with no statistically significant differences in incidence or severity between groups. Abrogation of the 5-LO pathway in mice indicates a lack of role of leukotrienes in Ang II-induced AAA pathogenesis stressing the need for additional non-rodent AAA pre-clinical models to be tested. 0 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:34 / 42
页数:9
相关论文
共 25 条
[1]   Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice [J].
Aiello, RJ ;
Bourassa, PA ;
Lindsey, S ;
Weng, WF ;
Freeman, A ;
Showell, HJ .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (03) :443-449
[2]   PHARMACOLOGY OF MK-0591 (3-[1-(4-CHLOROBENZYL)-3-(T-BUTYLTHIO)-5-(QUINOLIN-2-YL-METHOXY)-INDOL-2-YL]-2,2-DIMETHYL PROPANOIC ACID), A POTENT, ORALLY ACTIVE LEUKOTRIENE BIOSYNTHESIS INHIBITOR [J].
BRIDEAU, C ;
CHAN, C ;
CHARLESON, S ;
DENIS, D ;
EVANS, JF ;
FORDHUTCHINSON, AW ;
FORTIN, R ;
GILLARD, JW ;
GUAY, J ;
GUEVREMONT, D ;
HUTCHINSON, JH ;
JONES, TR ;
LEGER, S ;
MANCINI, JA ;
MCFARLANE, CS ;
PICKETT, C ;
PIECHUTA, H ;
PRASIT, P ;
RIENDEAU, D ;
ROUZER, CA ;
TAGARI, P ;
VICKERS, PJ ;
YOUNG, RN ;
ABRAHAM, WM .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1992, 70 (06) :799-807
[3]   Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice [J].
Daugherty, A ;
Manning, MW ;
Cassis, LA .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (11) :1605-1612
[4]   Mouse models of abdominal aortic aneurysms [J].
Daugherty, A ;
Cassis, LA .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (03) :429-434
[5]   Antagonism of AT2 receptors augments Angiotensin II-induced abdominal aortic aneurysms and atherosclerosis [J].
Daugherty, A ;
Manning, MW ;
Cassis, LA .
BRITISH JOURNAL OF PHARMACOLOGY, 2001, 134 (04) :865-870
[6]   Role of the renin-angiotensin system in the development of abdominal aortic aneurysms in animals and humans [J].
Daugherty, Alan ;
Rateri, Debra L. ;
Cassis, Lisa A. .
ABDOMINAL AORTIC ANEURYSM: GENETICS, PATHOPHYSIOLOGY AND MOLECULAR BIOLOGY, 2006, 1085 :82-91
[7]   Leukotrienes as mediators of airway obstruction [J].
Drazen, JM .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 158 (05) :S193-S200
[8]   Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis [J].
Dwyer, JH ;
Allayee, H ;
Dwyer, KM ;
Fan, J ;
Wu, HY ;
Mar, R ;
Lusis, AJ ;
Mehrabian, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (01) :29-37
[9]   Leukotriene modifiers as potential therapeutics for cardiovascular disease [J].
Funk, CD .
NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (08) :664-672
[10]   Prostaglandins and leukotrienes: Advances in eicosanoid biology [J].
Funk, CD .
SCIENCE, 2001, 294 (5548) :1871-1875